SCHEMBL9537344

SCHEMBL9537344

COc1ccc(C2CCC(=O)CC2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.56
CRBN Q96SW2 1/20 0.56
CYP3A4 P08684 1/20 0.45
ALDH1A1 P00352 2/20 0.41
CYP19A1 P11511 1/20 0.41
MAP2K3 P46734 1/20 0.41
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAOA P21397 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
PTGS2 P35354 1/20 0.40
RAB9A P51151 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
MMP1 P03956 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11637205 0.79 DDB1 (0.55) DDB1CRBNALDH1A1CYP19A1MAP2K3
SCHEMBL318066 0.78 MAPK1 (0.56) DDB1CRBNALDH1A1CYP19A1MAP2K3
SCHEMBL15874734 0.78 MAPK1 (0.56) DDB1CRBNALDH1A1CYP19A1MAP2K3
SCHEMBL11818914 0.77 GAA (0.41) DDB1CRBNALDH1A1SMN1; SMN2KMT2A
SCHEMBL1750687 0.77 LMNA (0.38) DDB1CRBNCYP3A4ALDH1A1CYP19A1
SCHEMBL1751794 0.77 DDB1 (0.50) DDB1CRBNCYP19A1KMT2ATP53
SCHEMBL11873333 0.77 MAPK1 (0.55) DDB1CRBNALDH1A1CYP19A1MAP2K3
SCHEMBL1506570 0.75 ESR2 (0.58) DDB1CRBNALDH1A1MAPK1SMN1; SMN2
SCHEMBL10451354 0.73 DDB1 (0.49) DDB1CRBNALDH1A1CYP19A1MAP2K3
SCHEMBL11821931 0.73 HTR2C (0.41) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200123127-A1 REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES EVERON BIOSCIENCES, INC. 2020-04-23 US disclosed
WO-2017189553-A1 REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES EVERON BIOSCIENCES, INC. (US) 2017-11-02 WO disclosed
EP-0291114-B1 OXIMINO ETHER COMPOUNDS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1993-08-25 EP disclosed
US-4921524-A HERBICIDES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1990-05-01 US disclosed
EP-0291114-A2 Oximino ether compounds SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123127-A1 REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES CD68, CD47, ARG1 DDB1 1200/4885CRBN 1539/4885CYP3A4 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.